SCHEMBL4424978

SCHEMBL4424978

CN(C)S(=O)(=O)c1ccc(Nc2ccc(C(=O)c3ccco3)c(N)n2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 3/20 0.67
MEN1 O00255 5/20 0.43
KMT2A Q03164 5/20 0.43
ALDH1A1 P00352 5/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
CCNB2 O95067 1/20 0.43
CCNE2 O96020 1/20 0.43
CDK1 P06493 1/20 0.43
CDK4 P11802 1/20 0.43
CCNB1 P14635 1/20 0.43
CCND1 P24385 1/20 0.43
CCNE1 P24864 1/20 0.43
CCNB3 Q8WWL7 1/20 0.43
RAB9A P51151 4/20 0.41
NPC1 O15118 3/20 0.41
LMNA P02545 2/20 0.41
CLK1 P49759 1/20 0.41
MAPT P10636 4/20 0.40
TSHR P16473 1/20 0.40
JAK2 O60674 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4411104 0.83 CDK2 (0.72) CDK2MEN1KMT2AALDH1A1CCNB2
SCHEMBL4421239 0.82 CDK2 (0.67) CDK2MEN1KMT2AALDH1A1CCNB2
SCHEMBL4412149 0.80 CDK2 (0.81) CDK2L3MBTL1CCNB2CCNE2CDK1
SCHEMBL6027265 0.70 CDK2 (0.73) CDK2MEN1KMT2AMAPT
SCHEMBL4422728 0.69 ALDH1A1 (0.51) MEN1KMT2AALDH1A1RAB9ANPC1
SCHEMBL4419524 0.67 CDK2 (1.00) CDK2CCNB2CCNE2CDK1CDK4
SCHEMBL4419088 0.62 CDK2 (0.74) CDK2MEN1KMT2AALDH1A1CDK1
SCHEMBL4414254 0.62 CDK2 (0.77) CDK2MEN1KMT2ACCNB2CDK1
SCHEMBL8179588 0.62 NAPRT (0.54) MEN1KMT2AALDH1A1RAB9ANPC1
SCHEMBL18616287 0.62 AURKA (0.53) CDK2MEN1KMT2ARAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1689394-A4 AMINO SUBSTITUTED PYRIDINYL METHANONE COMPOUNDS USEFUL IN TREATING KINASE DISORDERS JANSSEN PHARMACEUTICA NV (BE) 2009-06-03 EP disclosed
US-7109220-B2 Amino substituted pyridinyl methanone compounds useful in treating kinase disorders JANSSEN PHARMACEUTICA N.V. (BE) 2006-09-19 US disclosed
EP-1689394-A1 AMINO SUBSTITUTED PYRIDINYL METHANONE COMPOUNDS USEFUL IN TREATING KINASE DISORDERS JANSSEN PHARMACEUTICA N.V. (BE) 2006-08-16 EP disclosed
US-20050124610-A1 Amino substituted pyridinyl methanone compounds useful in treating kinase disorders JANSSEN PHARMACEUTICA N. V. (BE) 2005-06-09 US disclosed
WO-2005051387-A1 AMINO SUBSTITUTED PYRIDINYL METHANONE COMPOUNDS USEFUL IN TREATING KINASE DISORDERS JANSSEN PHARMACEUTICA N.V. (BE) 2005-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124610-A1 Amino substituted pyridinyl methanone compounds useful in treating kinase disorders CDK6, CDK1, CDK3 CDK2 4/4885MEN1 1273/4885KMT2A 640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.